Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4859314 | 0.99 | MCHR1 (0.47) | MCHR1ESR1ESR2ACHEACKR3 | |
| SCHEMBL13987530 | 0.89 | MCHR1 (0.60) | MCHR1 | |
| Hydrochloric Acid SCHEMBL4859576 | 0.88 | MCHR1 (0.59) | MCHR1 | |
| SCHEMBL4850731 | 0.88 | SIGMAR1 (0.42) | MCHR1ESR1ESR2ACHE | |
| SCHEMBL4855338 | 0.86 | MCHR1 (0.54) | MCHR1 | |
| SCHEMBL13987534 | 0.85 | MCHR1 (0.53) | MCHR1ACHE | |
| Hydrochloric Acid SCHEMBL4860606 | 0.85 | MCHR1 (0.53) | MCHR1 | |
| Hydrochloric Acid SCHEMBL4858727 | 0.84 | MCHR1 (0.53) | MCHR1ACHE | |
| SCHEMBL13987531 | 0.84 | MCHR1 (0.51) | MCHR1ESR1ESR2ACHE | |
| Hydrochloric Acid SCHEMBL4862441 | 0.83 | MCHR1 (0.51) | MCHR1ESR1ESR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | MCHR1 1502/4885ESR1 2300/4885ESR2 1201/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | MCHR1 1502/4885ESR1 2300/4885ESR2 1201/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | MCHR1 2885/4885ESR1 2575/4885ESR2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.